Live from the NIH registry
Studies recruiting near Cedar Rapids right now
Top 25 of 585 recruiting studies, sorted by proximity — each links to its official registry page
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma
Phase 2
Interventional 81 participants sought
University of Iowa/Holden Comprehensive Cancer Center — Iowa City, Iowa (22.4 mi)
· Sponsor: National Cancer Institute (NCI)
Palbociclib and Pembrolizumab in Sarcoma
Sarcoma
Phase 1
Interventional 8 participants sought
University of Iowa Hospitals & Clinics — Iowa City, Iowa (22.4 mi)
· Sponsor: John Rieth
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
B Acute Lymphoblastic Leukemia
Phase 2
Interventional 222 participants sought
University of Iowa/Holden Comprehensive Cancer Center — Iowa City, Iowa (22.4 mi)
· Sponsor: National Cancer Institute (NCI)
Cognitive Control to Boost Physical Activity Adherence
Physical Inactivity
N/A
Interventional 264 participants sought
Psychological and Brain Sciences Building — Iowa City, Iowa (22.4 mi)
· Sponsor: University of Iowa
Treatment of Moderate to Severe Refractory Crohn's Disease
Crohns Disease
Phase 1, Phase 2
Interventional 39 participants sought
University of Iowa — Iowa City, Iowa (22.4 mi)
· Sponsor: Tr1X, Inc.
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
Lymphoma, Large B-Cell, Diffuse
Phase 2
Interventional 594 participants sought
University of Iowa-Holden Comprehensive Cancer Center ( Site 0139) — Iowa City, Iowa (22.4 mi)
· Sponsor: Merck Sharp & Dohme LLC
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Multiple Myeloma, Relapsed/Refractory Multiple Myeloma
Phase 2
Interventional 100 participants sought
University of Iowa — Iowa City, Iowa (22.4 mi)
· Sponsor: C4 Therapeutics, Inc.
Progestins for the Treatment of Endometrial Cancer or Precancers of the Uterus Before Surgery, The Pro-Window Trial
Endometrial Endometrioid Adenocarcinoma, Endometrial Hyperplasia
Phase 2
Interventional 140 participants sought
University of Iowa/Holden Comprehensive Cancer Center — Iowa City, Iowa (22.4 mi)
· Sponsor: New Mexico Cancer Research Alliance
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Previously Treated Non-Small Cell Lung Cancer
Phase 2, Phase 3
Interventional 10,000 participants sought
Physicians' Clinic of Iowa PC — Cedar Rapids, Iowa (3.4 mi)
· Sponsor: SWOG Cancer Research Network
Biorepository and Registry for Plasma Exchange Patients
Antibody-mediated Rejection, NMO Spectrum Disorder
N/A
Observational 200 participants sought
DeGowin blood Center — Iowa City, Iowa (22.4 mi)
· Sponsor: Charles M Knudson
A Study to Evaluate the Safety of AB-1003 (Previously LION-101) in Subjects With Genetic Confirmation of LGMD2I/R9 (Part1)
Limb Girdle Muscular Dystrophy, Limb-Girdle Muscular Dystrophy Type 2
Phase 1, Phase 2
Interventional 10 participants sought
University of Iowa — Iowa City, Iowa (22.4 mi)
· Sponsor: AskBio Inc
A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria
Chronic Kidney Disease, Proteinuria
Phase 3
Interventional 100 participants sought
University of Iowa Health Care Medical Center - Nephrology — Iowa City, Iowa (22.4 mi)
· Sponsor: Bayer
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
Systemic Lupus Erythematosus
Phase 3
Interventional 450 participants sought
Sl0044 50319 — Iowa City, Iowa (22.4 mi)
· Sponsor: UCB Biopharma SRL
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer
Phase 3
Interventional 600 participants sought
University of Iowa — Iowa City, Iowa (22.4 mi)
· Sponsor: Hoffmann-La Roche
A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations
Advanced Pancreatic Carcinoma, Metastatic Pancreatic Carcinoma
Phase 2
Interventional 40 participants sought
Ohio State University-Telemedicine — Iowa City, Iowa (22.4 mi)
· Sponsor: Sameek Roychowdhury
A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy (EMPIRE)
Colo-rectal Cancer
Phase 2
Interventional 79 participants sought
University of Iowa - Holden Comprehensive Cancer Center — Iowa City, Iowa (22.4 mi)
· Sponsor: NSABP Foundation Inc
Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer 2
Bladder Cancer, Recurrent Bladder Cancer
N/A
Observational 408 participants sought
University of Iowa — Iowa City, Iowa (22.4 mi)
· Sponsor: University of Washington
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen
Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
Phase 3
Interventional 136 participants sought
University of Iowa Hospitals & Clinics- Holden Comprehensive Cancer Center — Iowa City, Iowa (22.4 mi)
· Sponsor: Servier Bio-Innovation LLC
Evaluation of Pirfenidone as a Novel Therapeutic Strategy Against Recurrent Acute Pancreatitis.
Recurrent Acute Pancreatitis
Phase 2
Interventional 60 participants sought
University of Iowa Health Care — Iowa City, Iowa (22.4 mi)
· Sponsor: University of Alabama at Birmingham
Studying the Presence of CFRD Complications With Thoughtful Recruitment (SPeCTRuM)
Cystic Fibrosis (CF), Cystic Fibrosis-related Diabetes
N/A
Observational 200 participants sought
University of Iowa — Iowa City, Iowa (22.4 mi)
· Sponsor: Jaeb Center for Health Research
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Acute Myeloid Leukemia (AML)
Phase 3
Interventional 1,300 participants sought
University of Iowa — Iowa City, Iowa (22.4 mi)
· Sponsor: Kura Oncology, Inc.
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
Large B-cell Lymphoma, Lymphoma, B-Cell
Phase 3
Interventional 400 participants sought
University of Iowa — Iowa City, Iowa (22.4 mi)
· Sponsor: Lyell Immunopharma, Inc.
Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC
Bladder Cancer, Non-Muscle Invasive Bladder Cancer (NMIBC)
Phase 2
Interventional 174 participants sought
University of Iowa — Iowa City, Iowa (22.4 mi)
· Sponsor: Michael A. O'Donnell
Sirolimus Pre-conditioning on T Cell Activity and T-cell Engaging Bispecific Antibody Efficacy in Multiple Myeloma
Multiple Myeloma
Phase 1
Interventional 10 participants sought
University of Iowa Health Care — Iowa City, Iowa (22.4 mi)
· Sponsor: Christopher Strouse
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
Smoldering Plasma Cell Myeloma
Phase 3
Interventional 288 participants sought
University of Iowa/Holden Comprehensive Cancer Center — Iowa City, Iowa (22.4 mi)
· Sponsor: ECOG-ACRIN Cancer Research Group